Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy

  • Tetsuya Inoue
  • Keiichiro Yoshinaga
  • Koichi Morita
  • Tohru Shiga
  • Kakuko Kanegae
  • Kenji Hirata
  • Shozo Okamoto
  • Nagara Tamaki


Iodine-131 metaiodobenzylguanidine (131I-MIBG) therapy is an effective treatment for patients with malignant paraganglioma for which surgical resection is not indicated. We performed high-dose 131I-MIBG therapy on two patients with malignant paraganglioma and multiple bone metastases. The bone metastases were diagnosed by magnetic resonance imaging (MRI). Metastatic bone lesions were evaluated by whole-body 131I-MIBG imaging and bone scintigraphy. Whole-body 131I-MIBG imaging showed extensive metastatic bone lesions, whereas conventional bone scintigraphy did not. There was a remarkable discrepancy between 131I-MIBG imaging and bone scintigraphy in the diagnosis of metastatic bone lesions of malignant paraganglioma in our two patients. High-dose 131I-MIBG imaging may detect early stages of bone metastases, compared with bone scintigraphy, in patients with malignant paraganglioma.

Key words

Paraganglioma Bone metastases 131I-MIBG therapy Bone scintigraphy 


  1. 1.
    Lee, JH, Barich, F, Karnell, LH, Robinson, RA, Zhen, WK, Gantz, BJ,  et al. 2002National cancer data base report on malignant paraganglioma of the head and neckCancer947307PubMedCrossRefGoogle Scholar
  2. 2.
    Zaplatnikov, K, Menzel, C, Dobert, N, Hamscho, N, Kranert, WT, Gotthard, M,  et al. 2004Drug interference with MIBG uptake in a patient with metastatic paragangliomaBr J Radiol775257PubMedCrossRefGoogle Scholar
  3. 3.
    Bomanji, JB, Hyder, SW, Gaze, MN, Gacinovic, S, Costa, DC, Coulter, C,  et al. 2001Functional imaging as an aid to decision-making in metastatic paragangliomaBr J Radiol742669PubMedGoogle Scholar
  4. 4.
    Hamilton, MA, Tait, D 2000Metastatic paraganglioma causing spinal cord compressionBr J Radiol739014PubMedGoogle Scholar
  5. 5.
    Basu, S, Nair, N 2006Stable disease and improved health-related quality of life (HRQoL) following fractionated low dose 131I-metaiodobenzyl-guanidine (MIBG) therapy in metastatic paediatric paraganglioma: observation on false “reverse” discordance during pre-therapy work up and its implication for patient selection for high dose targeted therapyBr J Radiol79e538PubMedCrossRefGoogle Scholar
  6. 6.
    Razakaboay, M, Maillefert, JF, Wendling, D, Juvin, R, Toussirot, E, Tavernier, C,  et al. 1999Bone metastases from a paraganglioma. A review of five casesRev Rheum Engl Ed668691Google Scholar
  7. 7.
    Hiller, WF, Scheumann, GF, Dralle, H 1993Diagnosis and surgical treatment of extra-adrenal pheochromocytomaChirurg643642PubMedGoogle Scholar
  8. 8.
    European association of nuclear medicine. Guidelines for 131I-meta iodo benzylguanidine thrapy. Available from: http://www.eanm.orgGoogle Scholar
  9. 9.
    Soderlund, V 1996Radiological diagnosis of skeletal metastasesEur Radiol658795PubMedCrossRefGoogle Scholar
  10. 10.
    Kaufman, RA, Thrall, JH, Keyes, JW,Jr, Brown, ML, Zakem, JF 1978False negative bone scans in neuroblastoma metastatic to the ends of long bonesAm J Roentgenol1301315Google Scholar
  11. 11.
    Hamaoka, T, Madewell, JE, Podoloff, DA, Hortobagyi, GN, Ueno, NT 2004Bone imaging in metastatic breast cancerJ Clin Oncol22294253PubMedCrossRefGoogle Scholar
  12. 12.
    Nakai, T, Okuyama, C, Kubota, T, Yamada, K, Ushijima, Y, Taniike, K,  et al. 2005Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancerEur J Nucl Med Mol Imaging3212538PubMedCrossRefGoogle Scholar
  13. 13.
    Fujimoto, R, Higashi, T, Nakamoto, Y, Hara, T, Lyshchik, A, Ishizu, K,  et al. 2006Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole body FDG-PETAnn Nucl Med20399408PubMedGoogle Scholar
  14. 14.
    Abe, K, Sasaki, M, Kuwabara, Y, Koga, H, Baba, S, Hayashi, K,  et al. 2005Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancerAnn Nucl Med195739PubMedCrossRefGoogle Scholar
  15. 15.
    Nakabeppu, Y, Nakajo, M 1994Radionuclide therapy of malignant pheochromocytoma with 131I-MIBGAnn Nucl Med825968PubMedCrossRefGoogle Scholar
  16. 16.
    Troncone, L, Rufini, V 1999Nuclear medicine therapy of pheochromocytoma and paragangliomaQ J Nucl Med4334455PubMedGoogle Scholar
  17. 17.
    Lenders, JW, Eisenhofer, G, Mannelli, M, Pacak, K 2005PheochromocytomaLancet36666575PubMedCrossRefGoogle Scholar
  18. 18.
    Sisson, JC, Shapiro, B, Beierwaltes, WH, Glowniak, JV, Nakajo, M, Mangner, TJ,  et al. 1984Radiopharmaceutical treatment of malignant pheochromocytomaJ Nucl Med25197206PubMedGoogle Scholar
  19. 19.
    Loh, KC, Fitzgerald, PA, Matthay, KK, Yeo, PP, Price, DC 1997The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patientsJ Endocrinol Invest2064858PubMedGoogle Scholar
  20. 20.
    Shapiro, B, Sisson, JC, Wieland, DM, Mangner, TJ, Zempel, SM, Mudgett, E,  et al. 1991Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experienceJ Nucl Biol Med3526976PubMedGoogle Scholar
  21. 21.
    Bauman, G, Charette, M, Reid, R, Sathya, J 2005Radiopharmaceuticals for the palliation of painful bone metastasis—a systemic reviewRadiother Oncol7525870PubMedGoogle Scholar
  22. 22.
    Gilbert, HA, Kagan, AR, Nussbaum, H, Rao, AR, Satzman, J, Chan, P,  et al. 1977Evaluation of radiation therapy for bone metastases: pain relief and quality of lifeAm J Roentgenol12910956Google Scholar
  23. 23.
    Goris, ML, Bretille, J 1985Skeletal scintigraphy for the diagnosis of malignant metastatic disease to the bonesRadiother Oncol331929PubMedCrossRefGoogle Scholar
  24. 24.
    Uematsu, T, Yuen, S, Yukisawa, S, Aramaki, T, Morimoto, N, Endo, M,  et al. 2005Comparison of FDG PET and SPECT for detection of bone metastases in breast cancerAm J Roentgenol184126673Google Scholar
  25. 25.
    Shulkin, BL, Shapiro, B, Hutchinson, RJ 1992I-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastomaJ Nucl Med33173540PubMedGoogle Scholar
  26. 26.
    Gordon, I, Peters, AM, Gutman, A, Morony, S, Dicks-Mireaux, C, Pritchard, J 1990Skeletal assessment in neuroblastoma—pitfalls of iodine-123-MIBG scanJ Nucl Med3112934PubMedGoogle Scholar
  27. 27.
    Hadj-Djilani, NL, Lebtahi, NE, Delaloye, AB, Laurini, R, Beck, D 1995Diagnosis and follow up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histologyEur J Nucl Med223229PubMedCrossRefGoogle Scholar
  28. 28.
    Maurea, S, Klain, M, Mainolfi, C, Ziviello, M, Salvatore, M 2001The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal massesJ Nucl Med4288492PubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2007

Authors and Affiliations

  • Tetsuya Inoue
    • 1
  • Keiichiro Yoshinaga
    • 2
  • Koichi Morita
    • 1
  • Tohru Shiga
    • 2
  • Kakuko Kanegae
    • 1
  • Kenji Hirata
    • 1
  • Shozo Okamoto
    • 1
  • Nagara Tamaki
    • 1
  1. 1.Department of Nuclear MedicineHokkaido University Graduate School of MedicineSapporoJapan
  2. 2.Department of Molecular ImagingHokkaido University Graduate School of MedicineSapporoJapan

Personalised recommendations